GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Related Articles
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy…
FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer
The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.
Dr Al Hallak on the Associated Risks of Cirrhosis and Portal Hypertension in HCC
Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.
Dose Reductions of Liposomal Irinotecan, Oxaliplatin Don’t Affect OS in Metastatic PDAC
Dose reductions of liposomal irinotecan and oxaliplatin did not compromise overall survival in patients with metastatic PDAC on NALIRIFOX.
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.
FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer
The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.
Novel Antibody-Drug Conjugate Gets Breakthrough Tx Designation for Rel/Ref Osteosarcoma
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
7th Interdisciplinary Pain and Opioid Crisis Seminar – MDA – Continuing Education (CE)
MDA, 7th Interdisciplinary Pain and Opioid Crisis Seminar, 4/25/2025 7:45:00 AM – 4/26/2025 2:00:00 PM, Clinical evidence supports the use of opioid analgesics as the…
H4K20me3-Mediated Repression of Inflammatory Genes Is a Characteristic and Targetable Vulnerability of Persister Cancer Cells
Cell persistence and senescence are distinct states of proliferative arrest induced by cancer therapy, with persister cells being characterized by the silencing of inflammatory genes…
